— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) —

— Subcutaneous formulation designed to provide gradual systemic exposure, potentially mitigating CRS risk —

ROCKVILLE, Md., Aug. 17, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical-stage biopharmaceutical...